Time filter

Source Type

Cabrera O.,Instituto Finlay Calle 17 E 198 Y 200 | Cuello M.,Instituto Finlay Calle 17 E 198 Y 200 | Thorn K.,University Gotemburgo | Peerson J.,University Gotemburgo | And 8 more authors.

Sexually transmitted infections by Herpes Simplex Virus type 2 (HSV-2) are the leading cause of genital ulcers and a major public health problem worldwide. This requires the use of mucosal vaccines, because parenteral vaccines have not been successful. Presently, there are not mucosal adjuvants, for this reason the development of adjuvants is essential for mucosal vaccine strategies. The intranasal (IN) immunizations using HSV-2 glycoprotein D (gD2), coadministered with cochleate (AFCo1+gD2), would be an efficient candidate for future vaccines against HSV2, similar to the gD2 incorporated into AFCo1(AFCo1-gD2). Female C57Bl/6 mice were inoculated with AFCo1-gD2, AFCo1+gD2 or gD2 alone by IN route. The anti gD2 IgG in sera and vaginal fluids and IgG subclasses were measured by ELISA. The lymphoproliferative response in spleen cells, the Th1/Th2 cytokine profile, the protection and the signs of disease against viral challenge were measured. High titers of IgG and IgG2c subclasses were observed in sera of mice that received the gD2 and AFCo1 as adjuvant. No significant differences (p>0.005) were observed in the animals that received AFCo1+gD2 or AFCo1-gD2. a preferential Th1 cytokine profile and 100% of survival after challenge were observed in both groups that received the gD2 and AFCo1, while no survival was observed in the group that only received the gD2. These results showed that the gD2 can be used coadministered with AFCo1 by IN route as a potential vaccine candidate against HSV-2. Source

Discover hidden collaborations